(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA to bring astronauts home from space station early due to a medical issue - 2What is the Significant Tech Expertise to Master Today?
- 3The Best Web-based Courses for Ability Advancement
- 441 Young Men Die in South Africa After Circumcision Initiation
- 5Wolf Bites Woman in Shocking Attack at Busy Shopping Center
- How to watch the last supermoon of the year
- Ancient fire discovery marks significant milestone in human history
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- Hungary's 'water guardian' farmers fight back against desertification
- 5 State of the art Advancements in Computer generated Simulation
- Historical mysteries solved by science in 2025
- Down to earth Manual for A Modest Hyundai Ioniq Electric for Seniors
- Picking the Right Home Machines: A Commonsense Aide
